Canaccord Genuity analyst John Newman maintained a Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) on Wednesday, setting a price target of $78, which is approximately 471.43% above the present share price of $13.65.
Newman expects Atara Biotherapeutics to post earnings per share (EPS) of -$0.95 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Atara Biotherapeutics, with an average price target of $41.8.
The analysts price targets range from a high of $78 to a low of $27.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$81.7 million. The company's market cap is $1.15 billion.
According to TipRanks.com, Canaccord Genuity analyst John Newman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.0% and a 43.98% success rate.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.